AN2 Therapeutics (ANTX) Enterprise Value (2021 - 2026)
AN2 Therapeutics (ANTX) reported Enterprise Value of -$85.3 million for Q1 2026, down 27.17% year-over-year from -$117.1 million in Q1 2025, and down 47.17% quarter-over-quarter from -$58.0 million in Q4 2025.
AN2 Therapeutics (ANTX) Enterprise Value (2021 - 2026) Analysis & Trends
AN2 Therapeutics (ANTX) has 6 years of Enterprise Value data on file, last reported at -$85.3 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$85.3 million, down 27.17% year-over-year; the trailing twelve-month figure through Mar 2026 was -$85.3 million (down 27.17% YoY), and the FY2025 annual result was -$58.0 million, up 30.68% from the prior year.
- Enterprise Value declined to -$85.3 million in Q1 2026 per ANTX's latest filing, from -$58.0 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$58.0 million in Q4 2025 and troughed at -$123.8 million in Q3 2023.
- A 5-year average of -$92.8 million and a median of -$95.2 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2022 and 2025: Enterprise Value sank 64.04% in 2022, then jumped 41.27% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$96.1 million in 2022, then fell by 11.65% to -$107.2 million in 2023, then grew by 22.03% to -$83.6 million in 2024, then jumped by 30.68% to -$58.0 million in 2025, then plunged by 47.17% to -$85.3 million in 2026.
- Business Quant data shows ANTX's Enterprise Value at -$85.3 million in Q1 2026, -$58.0 million in Q4 2025, and -$61.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.77 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -18.44 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -584.73 Mn |
| 10 | AN2 Therapeutics | 161.95 Mn | 161.95 Mn | - | -85.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -85.30 Mn |
| Dec 31, 2025 | -57.96 Mn |
| Sep 30, 2025 | -61.92 Mn |
| Jun 30, 2025 | -62.92 Mn |
| Mar 31, 2025 | -67.08 Mn |
| Dec 31, 2024 | -83.62 Mn |
| Sep 30, 2024 | -93.43 Mn |
| Jun 30, 2024 | -104.54 Mn |
| Mar 31, 2024 | -114.21 Mn |
| Dec 31, 2023 | -107.25 Mn |
| Sep 30, 2023 | -123.82 Mn |
| Jun 30, 2023 | -95.25 Mn |
| Mar 31, 2023 | -88.52 Mn |
| Dec 31, 2022 | -96.06 Mn |
| Sep 30, 2022 | -104.38 Mn |
| Jun 30, 2022 | -113.37 Mn |
| Mar 31, 2022 | -118.35 Mn |
| Dec 31, 2021 | -58.56 Mn |